1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 5, 2008, Pages 2419-2430

  Tabrizi, Mojgan Aghazadeh ^a   Baraldi, Pier Giovanni ^a   Preti, Delia ^a   Romagnoli, Romeo ^a   Saponaro, Giulia ^a   Baraldi, Stefania ^a   Moorman, Allan R ^b   Zaid, Abdel Naser ^c   Varani, Katia ^a   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Research and Development   (Italy)

^c AN NAJAH NATIONAL UNIVERSITY   (Palestine)

Author keywords

A2B antagonists; Adenosine receptors; Binding; Biological activity; Functional; Human; Phenylacetamide; Xanthine

Indexed keywords

2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 ETHYLPYRAZOL 1 YL] N (4 CHLOROPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (3 CHLOROPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (3 METHOXYLPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (3,4 DICHLOROPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (3,4 DIMETHOXYPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (3,4 DIMETHYLPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (4 BROMOPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (4 CHLOROPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (4 DIMETHYLAMINOPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (4 FLUOROPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (4 IODOPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (4 METHOXYPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (4 SEC BUTYLPHENYL)ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N 4 TOLYLACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N NAPHTHALEN 1 YL ACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N PHENYLACETAMIDE; 2 [3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL)PYRAZOL 1 YL] N (4 CHLOROPHENYL)ACETAMIDE; 2 [4 BROMO 3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (4 CHLOROPHENYL)ACETAMIDE; 2 [4 CHLORO 3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (4 CHLOROPHENYL)ACETAMIDE; 2 [4 IODO 3 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 5 METHYLPYRAZOL 1 YL] N (4 CHLOROPHENYL)ACETAMIDE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL REACTION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION;

HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PYRAZOLES; RECEPTOR, ADENOSINE A2B; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

EID: 40749109749     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.11.058     Document Type: Article

References (28)

1. Fredholm B.B., IJerman A.P., Jacobson K.A., Kloz KN., and Linden J. Pharmacol. Rev. 53 (2001) 527
2. Fredholm B.B. Drug News Perspect. 16 (2003) 283
3. Sawynok J. Handb Exp. Pharmacol. 177 (2007) 309
4. Armstrong J.M., Chen J.F., Schwarzschild M.A., Apasov S., Smith P.T., Caldwell C., Chen P., Figler H., Sullivan G., Fink S., Linden J., and Sitkovsky M. Biochem. J. 354 (2001) 123
5. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., and Freeman T.C. Br. J. Pharmacol. 118 (1996) 1461
6. Le Poole I.C., Yang F., Brown T.L., Cornelius J., Babcock G.F., Das P.K., and Boissy R.E. J. Invest. Dermatol. 113 (1999) 725
7. Varani K., Gessi S., Merighi S., Vincenzi F., Cattabriga E., Benini A., Klotz K.-N., Baraldi P.G., Tabrizi M.A., MacLennan S., Leung E., and Borea P.A. Biochem. Pharm. 70 (2005) 1601
8. Baraldi P.G., Tabrizi M.A., Preti D., Bovero A., Fruttarolo F., Romagnoli R., Moorman A.R., Gessi S., Merighi S., Varani K., and Borea P.A. Bioorg. Med. Chem. Lett. 14 (2004) 3607
9. Gessi S., Varani K., Meriggi S., Cattabriga E., Pancaldi C., Zabadkai Y., Rizzato R., Klotz K.-N., Leung E., Mac Lennan S., Baraldi P.G., and Borea P.A. Mol. Pharmacol. 67 (2005) 1
10. Martin P.L. Eur. J. Pharmacol. 216 (1992) 235
11. Ansari H.R., Nadeem A., Talukder M.A., Sakhalkar S., and Mustafa S.J. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H719
12. Dubey R.K., Gillespie D.G., Osaka K., Suzuki F., and Jackson E.K. Hypertension 27 (1996) 786
13. Dubey R.K., Gillespie D.G., Shue H., and Jackson E.K. Hypertension 35 (2000) 267
14. Varani K., Caramori G., Vincenzi F., Adcock I., Casolari P., Leung E., Maclennan S., Gessi S., Morello S., Barnes P.J., Ito K., Chung K.F., Cavallesco G., Azzena G., Papi A., and Borea P.A. Am. J. Respir. Crit. Care Med. 173 (2006) 398
15. Marx D., Ezeamuzie C.I., Nieber K., and Szelenyi I. Drug News Perspect. 14 (2001) 89
16. Holgate S.T. Br. J. Pharmacol. 145 (2005) 1009
17. Jacobson K.A., Ijzerman A.P., and Linden J. Drug. Dev. Res. 47 (1999) 45
18. Polosa R., and Holgate S.T. Curr. Drug Targets 7 (2006) 699
19. Volpini R., Costanzi S., Vittori S., Cristalli G., and Klotz K.-N. Curr. Top. Med. Chem. 3 (2003) 427
20. Baraldi P.G., Tabrizi M.A., Preti D., Bovero A., Romagnoli R., Fruttarolo F., Zaid N.A., Moorman A.R., Varani K., Gessi S., Merighi S., and Borea P.A. J. Med. Chem. 47 (2004) 1434
21. Pugmire R.J., and Grant D.M. J. Am. Chem. Soc. 90 (1968) 697
22. Baraldi P.G., Chiarini R., Budrieri M., Roberti A., Casolari A., Manfredini S., Simoni D., Zanirato V., Varani K., and Borea P.A. Drug Design Deliv. 5 (1989) 13
23. Varani K., Merighi S., Gessi S., Klotz K.-N., Leung E., Baraldi P.G., Cacciari B., Romagnoli R., Spalluto G., and Borea P.A. Mol. Pharmacol. 57 (2000) 968
24. Borea P.A., Dalpiaz A., Varani K., Gessi S., and Gilli G. Life Sci. 59 (1996) 1373
25. Varani K., Gessi S., Meriggi S., Iannotta V., Cattabriga E., Spisani S., Cadessi R., and Borea P.A. Br. J. Pharmacol. 136 (2002) 57
26. Bradford M. Anal. Biochem. 72 (1976) 248
27. Munson P.J., and Rodbard D. Anal. Biochem. 107 (1980) 220
28. Cheng Y., and Prusoff W.H. Biochem. Pharmacol. 1 (1973) 3099